Artemisinins for schistosomiasis and beyond

Area of Science:

• Parasitology
• Tropical Medicine
• Pharmacology

Background:

• Schistosomiasis affects over 200 million people globally, with morbidity impacting over half.
• Current morbidity control relies heavily on praziquantel, hindering development of new treatments.
• Praziquantel's efficacy and low cost have limited research into alternative schistosomiasis control methods.

Purpose of the Study:

• To review the antischistosomal activity of artemisinins.
• To summarize preclinical and clinical findings on artemisinin efficacy and safety.
• To explore artemisinins' potential in combination therapy and against other fluke infections and cancer.

Main Methods:

• Review of preclinical studies on artemisinins' antischistosomal effects.
• Analysis of clinical trial data on artemisinin safety and efficacy.
• Examination of artemisinin-based combination therapy in co-infected children.

Main Results:

• Preclinical studies demonstrate artemisinins possess antischistosomal activity.
• Clinical trials confirm the safety and efficacy of artemisinins.
• Artemisinins show promise against intestinal and liver flukes and cancer cells.

Conclusions:

• Artemisinins represent a promising alternative for schistosomiasis control.
• Further research into artemisinin-based therapies could advance treatment options.
• Artemisinins exhibit broad-spectrum activity beyond schistosomiasis, including potential anticancer properties.